Shares of Philip Morris extended their recent bounce Thursday after the U.S. Food and Drug Administration authorized the marketing of 20 of the tobacco company’s Zyn nicotine pouches.

The FDA said "an extensive scientific review" found the products were found to pose lower risks of cancer and other serious health conditions compared to cigarettes and smokeless tobacco products.

Tobacco stocks gained slightly on Thursday after the FDA has authorized the marketing of 20 Zyn nicotine pouch products through the premarket tobacco product application pathway. The development marks the first time the agency has approved nicotine pouches,